Adjusted High-dose Chemotherapy With Autologous Stem Cell Transplant vs. Conventional Immunochemotherapy in Elderly PCNSL Patients

NCT06830421 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

340

Enrollment

OTHER

Sponsor class

Conditions

Primary Central Nervous System Lymphoma

Interventions

DRUG: R-MP and Procarbazine maintenance
DRUG: R-MTX/AraC (MARTA) induction followed by consolidating HCT-ASCT

Sponsor

University Hospital Freiburg

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]